Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A hormone best known for curbing appetite may also be quietly protecting your liver. McMaster University researchers found that GDF15 activates a brain-to-liver signaling pathway that releases anti-inflammatory glucocorticoids, reducing liver inflammation and scarring — even without any weight loss. The findings could open new doors for treating advanced fatty liver disease (MASH).
A hormone already famous for suppressing appetite and aiding weight loss has a surprising second act: shielding the liver from inflammation and scarring. Researchers at McMaster University discovered that GDF15 activates a previously unknown brain-to-liver signaling pathway, triggering the release of glucocorticoids — steroid hormones that help calm the liver's immune response. Crucially, these protective effects occurred independently of changes in food intake, body weight, or liver fat.
The findings, published in Cell Metabolism on August 10, 2026, are particularly relevant for patients with metabolic dysfunction-associated steatohepatitis (MASH), an advanced form of fatty liver disease that can progress to cirrhosis, liver cancer, and liver failure. Even with today's effective weight-loss medications, liver inflammation can persist — and that's where this newly identified pathway could make a real difference.
Key Takeaways:
Why it matters: Millions worldwide live with MASH, and current treatments primarily target weight and liver fat — not inflammation directly. This discovery suggests the body has its own built-in liver defense system, and harnessing it could lead to more effective, targeted therapies.
